⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4907036 | 0.71 | LMNA (0.35) | — | |
| SCHEMBL5547319 | 0.69 | — | — | |
| SCHEMBL5542344 | 0.68 | TAAR1 (0.44) | — | |
| SCHEMBL2751318 | 0.67 | GRM5 (0.33) | — | |
| SCHEMBL2750686 | 0.67 | TTR (0.37) | — | |
| SCHEMBL332270 | 0.67 | — | — | |
| SCHEMBL1515182 | 0.67 | — | — | |
| SCHEMBL2752829 | 0.66 | NPC1 (0.39) | — | |
| SCHEMBL4366554 | 0.65 | MEN1 (0.43) | — | |
| Water SCHEMBL16432118 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1346 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4399212-A1 | SUBSTITUTED 2,3-DIHYDRO[1,3]THIAZOLO[4,5-B]PYRIDINES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2024-07-17 | — | — | EP | claimed |
| CN-118159542-A | Substituted 2, 3-dihydro [1,3] thiazolo [4,5-b ] pyridines, salts thereof and their use as herbicidal agents | 拜耳公司 | 2024-06-07 | — | — | CN | claimed |
| WO-2024034652-A1 | TERTIARY AMIDE DERIVATIVE SUBSTITUTED BY QUATERNARY CARBON | 住友ファーマ株式会社 | 2024-02-15 | — | — | WO | claimed |
| US-20240034737-A1 | Heterocyclic Derivatives as P2X7 Receptor Antagonists | BREYE THERAPEUTICS APS (DK) | 2024-02-01 | — | — | US | claimed |
| CN-117157291-A | Heterocyclic derivatives as P2X7 receptor antagonists | 布雷耶疗法有限公司 | 2023-12-01 | — | — | CN | claimed |
| US-20230355625-A1 | METHODS OF TREATMENT | INTRA-CELLULAR THERAPIES, INC. | 2023-11-09 | — | — | US | claimed |
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | claimed |
| EP-4262975-A1 | HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Breye Therapeutics ApS (DK) | 2023-10-25 | — | — | EP | claimed |
| WO-2023173131-A2 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-09-14 | — | — | WO | claimed |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | claimed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | claimed |
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | claimed |
| US-20040204454-A1 | Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | claimed |
| WO-2004082687-A1 | LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | claimed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | claimed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | claimed |
| WO-2003099276-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | claimed |
| US-6444679-B1 | NEUROLOGICAL AND GASTROINTESTINAL DISORDERS; DELTA OPIOID LIGANDS OR OPIOID RECEPTORS | PFIZER INC | 2002-09-03 | — | — | US | claimed |
| US-20020077323-A1 | Use of delta opioid receptor ligands and serotonin reuptake inhibitors in the treatment of chemical dependencies | PFIZER INC. | 2002-06-20 | — | — | US | claimed |
| EP-1038872-A1 | 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands | Pfizer Products Inc. (US) | 2000-09-27 | — | — | EP | claimed |